Autres langues Arcutis Biotherapeutics, Inc.

Actions

ARQT

US03969K1088

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 25/04/2024			Varia. 5j.	Varia. 1 janv.
8,59 ^USD	-1,83 %		-9,10 %	+165,94 %

11/03	Arcutis promeut Todd Tucker au poste de Chief Human Resources Officer	CI
10/03	Arcutis présente de nouvelles données de l'essai de phase 3 INTEGUMENT-PED sur le roflumilast crème 0,05% dans la dermatite atopique chez les enfants de 2 à 5 ans lors de la réunion annuelle de l'American Academy of Dermatology (AAD).	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Arcutis Appoints David Topper as Chief Financial Officer	10/04
Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes	10/04
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/04
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream	01/04
Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference	28/03
Arcutis Biotherapeutics, Inc.(NasdaqGS:ARQT) added to S&P Biotechnology Select Industry Index	18/03
Arcutis Promotes Todd Tucker to Chief Human Resources Officer	11/03
Arcutis Promotes Todd Tucker to Chief Human Resources Officer	11/03
Arcutis Biotherapeutics Says Atopic Dermatitis Cream Met Primary Endpoint in Phase 3 Study in Children	11/03
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting	10/03
Arcutis Presents Late-Breaking Data from INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 At the American Academy of Dermatology Annual Meeting	10/03
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting	10/03
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction	09/03
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction	09/03
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	06/03
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/03
Arcutis Biotherapeutics Raises $172.5 Million in Common Stock Offering	04/03
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares	04/03
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting	04/03
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting	04/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Arcutis Biotherapeutics, Inc.

Actions

ARQT

US03969K1088

Autres langues

Filtres